Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials

Figures & data

Table 1 Proportion of ASAS20 responders in the GO-RAISE and GO-AHEAD studies

Study	Placebo	Golimumab 50 mg	Golimumab 60 mg
GO-RAISE, primary end point at Week 14^Citation15	21.8	59.4	60
GO-RAISE, 2 years^Citation17	38.5	60.1	71.4
GO-AHEAD, primary end point at Week 16^Citation16	40	71.1	NA

Abbreviations: ASAS, Assessment of SpondyloArthritis international Society; NA, not available.

InmanRDDavisJCJrHeijdeDEfficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trialArthritis Rheum200858113402341218975305

 PubMed Web of Science ®Google Scholar

BraunJDeodharAInmanRDGolimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE studyAnn Rheum Dis201271566166722012970

 PubMed Web of Science ®Google Scholar

SieperJvan der HeijdeDDougadosMA randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisArthritis Rheumatol201567102702271226139307

 PubMed Web of Science ®Google Scholar